Cancer Diagnostics – News and Features

Researchers developed a three-dimensional, in vitro culture system containing an artificial blood vessel and intestinal tumor organoids, small pieces of tumor-like tissue, but learn how tumor cells access the bloodstream.

An artificial intelligence technique for detecting DNA fragments shed by tumors and circulating in a patient’s blood could help clinicians more quickly identify and determine if pancreatic cancer therapies are working.

Mass General Brigham researchers developed HPV-DeepSeek, a liquid biopsy blood test achieving 99% sensitivity for early detection of HPV-associated head and neck cancers. The test offers a highly accurate screening method.

Researchers have created a new kind of nanoparticle that could make ultrasound-based cancer treatments more effective and safer, while also helping prevent tumors from coming back.

Liquid biopsies offer a less invasive, yet highly informative, alternative to traditional diagnostic methods. This article examines how liquid biopsies are aiding cancer drug development and guiding treatment strategies.

New research led by Irish scientists has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central role in weakening the body’s immune response in advanced ovarian cancer.

Two new advanced predictive algorithms use information about a person’s health conditions and simple blood tests to accurately predict a patient’s chances of having a currently undiagnosed cancer, including hard-to-diagnose liver and oral cancers.

Stanford Medicine researchers have created a liquid biopsy test capable of detecting cancers, molecular mechanisms of resistance to treatment and tissue injury.

Researchers showed that approximately 80 percent of stage 3 melanoma patients who had detectable levels of circulating tumor DNA (ctDNA) before they started treatment to suppress their tumors went on to experience recurrence.

Researchers used mutational analysis to identify gene mutations that may drive carcinogenesis in colorectal tumors with high tumor mutation burden.